Position in PFE
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$46,156,568
-$7,594,701 QoQ
Shares Held
1,916,801
+0.1% QoQ
Ownership
0.034%
of shares outstanding
% of Portfolio
0.50%
of 13F equity value
Holder Rank
#184
of 2,826 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 68%
Shared 0%
None 32%
Common Shares in PFE Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026CAUSEWAY CAPITAL MANAGEMENT LLC holds $2,118,676,056 across 8 Drug Manufacturers - General names. PFE ranks #5 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
9,357,390 | $1,774,348,291 | |
| 2 | MRK |
Merck & Co., Inc.
|
954,932 | $122,708,762 | |
| 3 | NVO |
Novo Nordisk A S
|
1,677,615 | $80,424,863 | |
| 4 | BIIB |
Biogen Inc.
|
278,283 | $60,125,824 | |
| 5 | PFE |
Pfizer Inc
This page
|
1,916,801 | $46,156,568 | |
| 6 | SNY |
Sanofi
|
804,056 | $34,301,028 | |
| 7 | GSK |
GSK plc
|
7,163 | $375,484 | |
| 8 | NVS |
Novartis AG
|
1,501 | $235,236 |
All Filings in PFE
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $46,156,568 | 1,916,801 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $53,751,269 | 1,914,219 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $52,083,803 | 2,091,719 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $52,795,757 | 2,072,047 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $47,590,682 | 1,963,312 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $51,294,621 | 2,024,255 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $48,623,918 | 1,832,790 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $63,995,311 | 2,211,310 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $56,062,378 | 2,003,659 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||